Peptide compound for inhibiting restenosis and promoting re-endothelialization and method for preparing the same

ABSTRACT

Provided are a peptide compound prepared by additional synthesis in a drug having an effect of inhibiting restenosis, a composition for inhibiting restenosis and promoting re-endothelialization including the peptide compound, and a stent having a surface coated by using the composition, in order to overcome a restenosis problem in the stent.

CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority to Korean Patent Application No.10-2014-0074700 filed Jun. 19, 2014, the disclosure of which is herebyincorporated in its entirety herein by reference.

REFERENCE TO A SEQUENCING LISTING

The Sequence Listing associated with this application is filed inelectronic format via EFS-Web and is hereby incorporated by referenceinto the specification in its entirety. The name of the text filecontaining the Sequence Listing is 154859_ST25.txt. The size of the textfile is 574 bytes, and the text file was created on Jan. 8, 2016.

TECHNICAL FIELD

The following disclosure relates to a peptide compound for inhibitingrestenosis and promoting re-endothelialization and a method forpreparing the same.

BACKGROUND

In accordance with the recent trend of an aging society, a coronaryartery disease such as angina pectoris, myocardial infarction, or thelike, has increased at a rapid rate in adults in Korea over the last 10years, and is the highest cause of death except for cancer. The coronaryartery disease is a disease that occurs in blood vessels surrounding theheart, and causes blood supply disorder in the heart muscle. The mostcommon cause of the coronary artery disease is arteriosclerosis. Whenplaque made by a combination of cholesterol and other fats accumulate incoronary arteries, and various other components in blood arecorrespondingly increased, which cause coronary stenosis, andaccordingly, blood supply to the heart muscle is reduced, which resultsin lack of nutrients and oxygen. As a result, it may cause chest pain(angina) or myocardial infarction, and even worse, lead to death.

Therefore, as a method of treating the diseases occurring in the bloodvessels, a treatment method of expanding blood vessel passages narroweddue to stenosis by using an implantation tool called a stent has beengenerally and frequently used.

When stenosis or occlusion occurs in vascular or nonvascular lumen in ahuman body, the stent is a general term for medical devices for thepurpose of opening the lumen. The stent was first suggested by CharlesR. Stent at the end of the 19th Century, while stent implantation wasfirst attempted in the peripheral artery by Charles Dotter in 1969, anda stent having a single spiral structure was invented by Maass in the1980s.

The stent placement surgery using the stent is most common in terms ofmost treatment methods for a cardiovascular disease due to a lowrestenosis effect and a previously proven treatment effect, and usagefrequency and reliability of the stent have continuously increased. Inaddition, recently, research into localization of a drug-eluting stent(DES) in the country has also been actively ongoing.

The drug-eluting stent (DES) in which a drug is directly delivered to acell or a tissue by coating the drug on a surface of the stent so as toreduce restenosis in the stent was developed and usage thereof has beengradually increased.

However, after the stent placement surgery, damage occurs in the bloodvessel which induce proliferation of smooth muscle cells according to animmune response to the stent at an initial induction, and problems suchas in-stent restenosis (IRS) by smooth muscle cells proliferated in theblood vessels and acute thrombosis, late thrombosis, inflammation by apolymer used in coating, and the like occur.

Although a number of researches for solving the above-described problemshave been conducted, most of them are to use drug coating technology forstandardized drug controlled release capable of preventing restenosis,or is on the basis of inhibition of restenosis, and are limited todevelop a drug coated stent simply controlling a drug in a continuousway rather than a coating technology for controlling a drug releaseaccording to a vascular therapy mechanism. Drugs currently used forcommercially available DES are sirolimus or -limus family drugs that area substitute for sirolimus, which are effective for inhibitingrestenosis, but do not solve problems caused by DES usage, which is notsufficient in inhibiting inflammation, promoting re-endothelialization,inhibiting late thrombosis, and the like.

RELATED ART DOCUMENT

(Patent Document 1) Korean Patent Laid-Open Publication No. KR2014-0038941 A

SUMMARY

In order to overcome a restenosis problem in a stent, an embodiment ofthe present invention is directed to providing a novel peptide compoundcapable of promoting re-endothelialization in blood vessels byadditional synthesis in a drug having an effect of inhibitingrestenosis, and a stent having a surface coated by using the same.

In one general aspect, there is a peptide compound represented byChemical Formula 1 below:

In another general aspect, a method for preparing a peptide compoundincludes:

reacting a compound represented by Chemical Formula 2 below with acompound represented by Chemical Formula 3 below to prepare a compoundrepresented by Chemical Formula 4 below; and

reacting the compound represented by Chemical Formula 4 below with acompound represented by Chemical Formula 5 below to prepare the compoundrepresented by Chemical Formula 1 below:

In another general aspect, there is a composition for inhibitingrestenosis and promoting re-endothelialization including a peptidecompound represented by Chemical Formula 1 below:

In another general aspect, there is a stent including the compositionfor inhibiting restenosis and promoting re-endothelialization asdescribed above.

The stent may be a stent for preventing or treating a cardiovasculardisease.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph showing an efficacy for inhibiting cell proliferationto vascular smooth muscle cell (SMC) of a peptide compound according tothe present invention.

FIG. 2 is a graph showing an efficacy for promoting cell proliferationto human umbilical vein endothelial cell (HUVEC) of the peptide compoundaccording to the present invention.

DETAILED DESCRIPTION OF EMBODIMENTS

Hereinafter, the present invention will be described in more detail.

The present invention provides a novel peptide compound capable ofinhibiting restenosis due to acute thrombosis easily occurring as a sideeffect after stent placement surgery in a human body and promotingre-endothelialization.

The novel peptide compound of the present invention is represented byChemical Formula 1 below:

The novel peptide compound represented by Chemical Formula 1 of thepresent invention is a compound having an efficacy for preventing themost common side effect after a stent implantation in a human body.

The peptide having a sequence of WKYMIRV (SEQ ID NO: 1) has an excellenteffect in promoting endothelial cell proliferation and reinforcingfunctions of the endothelial cell.

Preferably, the peptide may be a peptide in which fluorophores arelabeled on the peptide having a sequence of WKYMIRV (SEQ ID NO: 1).

The fluorophores are not limited, but may be used as long as it iscapable of being labeled on the peptide. For example, cy5.5, Rhodamin,FITC, GFP may be used, and fluorescein isothiocyanate (FITC) among thefluorophores is the most preferred.

A peptide compound represented by Chemical Formula 1 above, havingsynthesized peptide having a sequence of WKYMIRV (SEQ ID NO: 1),according to an exemplary embodiment of the present invention may besynthesized by the following reaction.

A compound represented by Chemical Formula 4 below may be prepared byreacting Everolimus which is a compound represented by Chemical Formula2 below with a malonic acid which is a compound represented by ChemicalFormula 3 below to substitute an —OH group at the left end of theEverolimus with a carboxylic group.

A novel bidirectional functional compound which is the compoundrepresented by Chemical Formula 1 may be synthesized by an amide bond(—CONH) which is a chemical bond formed by reacting the carboxylic groupof the compound represented by Chemical Formula 4 and an amino group ofthe peptide, and therefore, NH of the compound represented by ChemicalFormula 1 is provided by the reaction of the carboxylic group of thecompound represented by Chemical Formula 4 and the amino group of thepeptide.

In addition, the present invention provides a method for preparing apeptide compound represented by Chemical Formula 1 below. According toan exemplary embodiment of the present invention, the method forpreparing the peptide compound represented by Chemical Formula 1 belowincludes reacting the compound represented by Chemical Formula 2 belowwith the compound represented by Chemical Formula 3 below to prepare thecompound represented by Chemical Formula 4 below; and reacting thecompound represented by Chemical Formula 4 below with a compoundrepresented by Chemical Formula 5 below to prepare the compoundrepresented by Chemical Formula 1 below:

A solvent used in the preparation method of the present invention is notlimited as long as it is a general organic solvent. For example, thesolvent may be at least one kind selected from the group consisting of(C1-C10)polyol such as ethanol, methanol, isopropanol, or the like,normal hexane (n-hexane), cyclohexane, normal pentane (n-pentane),diethyl ether (ether), toluene, tetrahydrofuran (THF), dichloromethane(DCM), and trichloromethane (chloroform).

A reaction temperature in the preparation method of the presentinvention is not limited as long as it is a temperature used in generalorganic synthesis, but may vary according to a reaction time, an amountof a reaction material and a starting material. After completeconsumption of the starting material is confirmed by NMR, GC, and thelike, the reaction is completed. When the reaction is completed, thesolvent may be removed by simple distillation under reduced pressureafter filtration, and then a desired material may be separated andrefined by general methods such as fractional distillation, ordistillation under reduced pressure, and the like.

According to another embodiment, the present invention provides acomposition for inhibiting restenosis and promotingre-endothelialization including the peptide compound.

The compound represented by Chemical Formula 2 used in the preparationmethod of the present invention is Everolimus which is one of the -limusfamily of immunosuppressive compounds developed by Novartis.

Everolimus, which is the -limus family drug currently mainly used forcommercially available DES as a drug for treating a cardiovasculardisease, which is represented by Chemical Formula 2, is effective forinhibiting restenosis, but is not sufficient for inhibitinginflammation, promoting re-endothelialization, inhibiting latethrombosis, and the like. Therefore, the present invention provides acomposition for inhibiting restenosis and promotingre-endothelialization including the peptide compound capable of not onlyinhibiting restenosis, but also promoting re-endothelialization toinhibit late thrombosis by synthesizing the peptide which promotesre-endothelialization at the end of Everolimus represented by ChemicalFormula 2.

Specifically, the novel peptide compound synthesized with the peptidehaving an effect of promoting proliferation of an endothelial cell andreinforcing function of the endothelial cell together with an efficacyof the existing Everolimus, that is an effect of inhibiting restenosisdue to acute thrombosis may inhibit restenosis due to acute thrombosiswhich may occur after stent implantation in a human body and may promotere-endothelialization to prevent a delay of re-endothelializationformation caused by inflammation.

According to another embodiment, the present invention provides a stentincluding the composition for inhibiting restenosis and promotingre-endothelialization.

The stent having a surface coated by the novel peptide compound is astent for inhibiting restenosis due to thrombosis that occurs afterstent placement surgery in a human body and promotingre-endothelialization.

The stent used in the present invention is not specifically limited, butgenerally refers to an implantable structure such as an in-vivoimplantable structure, an in-vivo implantable medical device, or thelike, and means a stent usable for various purposes. As an example, thestent may be a stent for esophageal implantation used according tocauses of stenosis of the esophagus or pylorus, gastroesophagealjunction, or a stent for a cardiovascular disease which is implantablefor a coronary artery disease or a cardiovascular disease, but is notspecifically limited. The stent utilized for cardiovascular disease ispreferred.

A material of the stent is also not limited, but may be a metal or aplastic.

The cardiovascular disease refers to diseases occurring in heart andmajor arteries. Major diseases of cardiovascular disease may be highblood pressure, ischemic heart disease, coronary artery disease, anginapectoris, myocardial infarction, atherosclerosis (arteriosclerosis),cerebrovascular disease, stroke, and arrhythmia, but the presentinvention is not specifically limited thereto.

Hereinafter, the present invention will be described in more detail withreference to the following exemplary embodiments. However, the followingexemplary embodiments are provided by way of example, and therefore, thepresent invention is not limited thereto.

Example 1 Synthesis of Peptide Compound (EVR-P)

(1) Synthesis of Everolimus with COOH

A compound represented by Chemical Formula 4 above was synthesized bymixing Everolimus (LC Laboratories) as a starting material and malonicacid (Sigma-Aldrich) at a molar ratio of 1:1 to 2 and reacting andstirring the mixture in a methanol solvent at room temperature for 10hours.

(2) Synthesis of Peptide Compound (EVR-P)

A peptide compound (EVR-P) was prepared by mixing the above-preparedpeptide represented by Chemical Formula 4 and a peptide represented byChemical Formula 5 at a molar ratio of 1:2 and reacting the mixture in amethanol solvent for 10 hours. For activation of the peptide compound(EVR-P), EDC(1-Ethyl-3-[3-dimethylaminopropyl]carbodiimidehydrochloride)(Sigma-Aldrich) and NHS(N-hydroxysulfosuccinimide)(Sigma-Aldrich) were added thereto, and additionally reacted at roomtemperature for 11 hours. The peptide compound (EVR-P) and EDC weremixed and reacted at a molar ratio of 1:3 m and the peptide compound(EVR-P) and NHS were mixed and reacted at a molar ratio of 1:3 tosynthesize a final peptide compound (EVR-P).

Example 2 Cell Culture for Experiment Confirming Effect of PeptideCompound on Cell Proliferation

An experiment confirming an effect of the compound prepared by Example 2on a vascular smooth muscle cell (SMC), which is a main cause ofrestenosis occurring in blood vessels after stent implantation in ahuman body, and on a human umbilical vein endothelial cell (HUVEC),which is a cell for promoting vascular re-endothelialization, wasconducted.

As cells used in a cell culture, the vascular smooth muscle cell (SMC)which is a smooth muscle cell, and the human umbilical vein endothelialcell (HUVEC) which is the cell for promoting vascularre-endothelialization were purchased from Korea Cell Line Bank,respectively. The cell culture was performed by culturing the vascularsmooth muscle cell (SMC) and the human umbilical vein endothelial cell(HUVEC) in Dulbecoco's modified eagle medium (DMEM) with 10% fetalbovine serum (FBS) under conditions of 37° C. and 5% CO₂.

The cells were cultured in a disposable cell culture flask, and upon anexperiment, the cells were cultured in the 24-well cell culture plateaccording to an experimental method.

Example 3 Effect of Peptide Compound on Proliferation of Vascular SmoothMuscle Cell (SMC)

An experiment for measuring restenosis inhibition andre-endothelialization promotion effects of the peptide compound preparedby Example 1 was conducted by using the vascular smooth muscle cell(SMC) which is a main cause of restenosis in cell proliferation. Resultsthereof were shown in FIG. 1.

5×10⁴ of SMC cells cultured according to Example 2 were cultured in the24-well cell culture plate and then treated with 1 uM of the peptidecompound prepared by Example 2 (hereinafter, referred to as ‘EVR-P’). Agroup which was not treated with the compound was used as a positivecontrol group (control). After treatment with the compound, 40 ul ofXTT-regent (EZ-Cytox cell viability assay kit, Daeil Lab., Korea) wastreated at 1, 4, and 7 days, respectively, and reacted for 2 hours.After the reaction, 200 ul of the culture medium was transferred fromeach well to a 96 well cell culture dish, and degree of color change wasmeasured from absorbance at a 450 nm wavelength by a spectroscopy.Results thereof were shown in FIG. 1.

Example 4 Effect of Peptide Compound on Proliferation of Human UmbilicalVein Endothelial Cell (HUVEC)

An experiment for measuring restenosis inhibition andre-endothelialization promotion effects of the peptide compound preparedby Example 1 was conducted by using the human umbilical vein endothelialcell (HUVEC) which is a cell for promoting vascularre-endothelialization in cell proliferation. Results thereof were shownin FIG. 2.

5×10⁴ of HUVEC cells cultured according to Example 2 were cultured inthe 24-well cell culture plate and then treated with 1 uM of the peptidecompound (EVR-P) prepared by Example 1. A group which was not treatedwith the compound was used as a positive control group (control). Aftertreatment with the compound, 40 ul of XTT-regent (EZ-Cytox cellviability assay kit, Daeil Lab., Korea) was treated at 1, 4, and 7 days,respectively, and reacted for 2 hours. After the reaction, 200 ul of theculture medium was transferred from each well to the 96 well cellculture dish, and degree of color change was measured by usingabsorbance at a 450 nm wavelength by a spectroscopy. Results thereofwere shown in FIG. 2.

Comparative Example 1 Effect of Known Everolimus on SMC Proliferation

5×10⁴ of SMC cells cultured according to Example 2 were cultured in the24-well cell culture plate and then treated with 1 uM of the knownEverolimus (EVR)(LC Laboratories). A group with non-treated cells wasused as a positive control group (control). After treatment with thecompound, 40 ul of XTT-regent (EZ-Cytox cell viability assay kit, DaeilLab. Korea) was treated at 1, 4, and 7 days, respectively, and reactedfor 2 hours. After the reaction, 200 ul of the culture medium wastransferred from each well to the 96 well cell culture dish, and degreeof color change was measured from absorbance at a 450 nm wavelength by aspectroscopy. Results thereof were shown in FIGS. 1 and 2.

Comparative Example 2 Effect of Known Everolimus on HUVEC Proliferation

5×10⁴ of HUVEC cells cultured according to Example 2 were cultured inthe 24-well cell culture plate and then treated with 1 uM of the knownEverolimus (EVR)(LC Laboratories). A group with non-treated cells wasused as a positive control group (control). After treatment with thecompound, 40 ul of XTT-regent (EZ-Cytox cell viability assay kit, DaeilLab. Korea) was treated at 1, 4, and 7 days, respectively, and reactedfor 2 hours. After the reaction, 200 ul of the culture medium wastransferred from each well to 96 well cell culture dish, and degree ofcolor change was measured from absorbance at a 450 nm wavelength by aspectroscopy. Results thereof were shown in FIGS. 1 and 2.

Hereinafter, experimental results of Examples 3 and 4 and ComparativeExamples 1 and 2 were explained as follows.

In comparison results between Example 3 according to the presentinvention and Comparative Example 1, the positive control group to whichthe compound according to Example 1 (EVR-P) was not added continuouslygrew until 7 days. Meanwhile, cell proliferation was inhibited in a casetreated with EVR-P according to Example 3 and in a case treated with EVRaccording to Comparative Example 1. It was determined as a cellproliferation inhibition effect by mTOR binding domain of Everolimus.That is, when it was considered that the efficacy for inhibiting SMCproliferation of EVR-P prepared by the present invention was similar toEverolimus (EVR), it was confirmed that EVR-P which is a novel compoundprepared by peptide synthesis using Everolimus (EVR) according to thepresent invention did not affect the efficacy for inhibiting muscle cellproliferation of the Everolimus (EVR).

In addition, in comparison results between Example 4 and ComparativeExample 2, the positive control group to which EVR-P according toExample 1 was not added continuously grew until 7 days. Meanwhile, HUVECcell proliferation was more improved in a case treated with EVR-Paccording to Example 4 as compared to a case treated with EVR accordingto Comparative Example 2. It indicated that proliferation ofre-endothelialization is restored due to the EVR-P according to thepresent invention which is similar to the positive control group, and itproved that the peptide according to the present invention is a factorfor promoting endothelial cell proliferation.

Therefore, it indicated that the peptide compound represented byChemical Formula 1 prepared according to the present invention had aneffect of inhibiting restenosis and promoting re-endothelialization.

According to the present invention, there are a peptide compound byadditional synthesis in a drug having an effect of inhibitingrestenosis, and a composition for inhibiting restenosis and promotingre-endothelialization including the peptide compound. Restenosis in thestent which is a problem of a drug-eluting stent (DES) may be inhibitedand re-endothelialization may be promoted by coating the composition onthe stent.

What is claimed is:
 1. A peptide compound represented by ChemicalFormula 1 below: